NASDAQ:HOLX - Hologic Stock Price, Price Target & More

$38.36 -0.26 (-0.67 %)

(As of 04/25/2018 10:24 AM ET)

Previous Close$38.62

Today's Range$38.25 - $38.61

52-Week Range$35.33 - $46.80

Volume163,055 shs

Average Volume2.57 million shs

Market Capitalization$10.63 billion

P/E Ratio19.02

Dividend YieldN/A

Beta0.85

About Hologic (NASDAQ:HOLX)

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. It offers Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and related products, and accessories comprising digital and film-based mammography systems; computer-aided detection for mammography; minimally invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. In addition, it offers Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D, a software product that provides 2D images; Selenia digital mammography platform; and SecurView Workstation. Further, it provides SculpSure, MonaLisa Touch, Vectus diode, and Cellulaze laser devices; PicoSure and Icon aesthetic systems; MedLite, RevLite, Cynergy, Elite, and SmartLipo products; and system components. Additionally, it offers NovaSure system to treat women suffering from abnormal uterine bleeding; MyoSure system for the hysteroscopic removal of fibroids; discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry X-ray apparatus & tubes

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNASDAQ:HOLX

CUSIP43644010

Webwww.hologic.com

Phone508-263-2900

Debt

Debt-to-Equity Ratio0.87%

Current Ratio1.25%

Quick Ratio0.98%

Price-To-Earnings

Trailing P/E Ratio19.02

Forward P/E Ratio17.05

P/E Growth1.73

Sales & Book Value

Annual Sales$3.06 billion

Price / Sales3.47

Cash Flow$3.6603 per share

Price / Cash10.48

Book Value$9.93 per share

Price / Book3.86

Profitability

EPS (Most Recent Fiscal Year)$2.03

Net Income$755.50 million

Net Margins34.53%

Return on Equity20.07%

Return on Assets7.11%

Miscellaneous

Employees6,233

Outstanding Shares276,530,000

How to Become a New Pot Stock Millionaire

Hologic (NASDAQ:HOLX) Frequently Asked Questions

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic (NASDAQ:HOLX) issued its quarterly earnings results on Thursday, February, 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.50 by $0.05. The medical equipment provider earned $791.10 million during the quarter, compared to analyst estimates of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.07%. Hologic's quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.52 EPS. View Hologic's Earnings History.

When is Hologic's next earnings date?

Hologic is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Hologic.

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its second quarter earnings guidance on Thursday, February, 8th. The company provided earnings per share (EPS) guidance of $0.53-0.54 for the period, compared to the Thomson Reuters consensus estimate of $0.55. The company issued revenue guidance of $770-785, compared to the consensus revenue estimate of $790.90 million.

What price target have analysts set for HOLX?

13 Wall Street analysts have issued twelve-month price targets for Hologic's stock. Their forecasts range from $42.00 to $52.00. On average, they anticipate Hologic's stock price to reach $47.5385 in the next twelve months. View Analyst Ratings for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:

1. According to Zacks Investment Research, "Over the past three months, Hologic has been underperforming the broader industry. The company's blood screening divestiture continues to impede growth. Foreign currency headwinds and a competitive landscape also continue to pose challenges for the company. On a positive note, Hologic has been witnessing strength in the Molecular Diagnostics. Moreover, growth across all geographical regions buoys optimism. Buoyed on differentiated products, Breast Health has been performing well. We are upbeat about the recent CE Mark approval for Brevera breast biopsy system. Also, the PMA approval for the Aptima HBV Quant Assay for quantitation of hepatitis B viral load on the fully automated Panther system buoys optimism. Hologic’s strong cash position is encouraging." (3/6/2018)
2. Needham & Company LLC analysts commented, "HOLX’s F1Q18 revenue was consistent with its 1/8/18 preannouncement while its EPS beat consensus. Management reiterated its FY18 revenue guidance and raised its EPS guidance due to tax reform. We note that HOLX expects to reinvest about half of its tax savings in marketing campaigns and R&D. HOLX’s organic revenue growth increased to 4.9% (adjusted for selling days) in F1Q18 from 4.4% in F4Q17. Breast Health growth improved from last quarter driven by the stronger international sales while Diagnostics growth (excluding the Blood divestiture) slowed. We expect HOLX’s revenue growth to accelerate as its Aesthetics business returns to Y/Y growth and it faces easier comps and we reiterate our Buy rating." (2/9/2018)

Who are some of Hologic's key competitors?

Some companies that are related to Hologic include Express Scripts (ESRX), Zoetis (ZTS), Beximco Pharmaceuticals (BXP), Humana (HUM), Vertex Pharmaceuticals (VRTX), Boston Scientific (BSX), Baxter International (BAX), Illumina (ILMN), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Hospital Co. of America (HCA), McKesson (MCK), Essilor International (ESLOY), Fresenius Medical Care (FMS) and Astellas Pharma (ALPMY).

Who are Hologic's key executives?

Hologic's management team includes the folowing people:

Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 54)
Mr. Robert W. McMahon, Chief Financial Officer (Age 49)
Mr. John M. Griffin, Gen. Counsel (Age 57)
Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 55)
Mr. Eric B. Compton, Consultant (Age 53)

Has Hologic been receiving favorable news coverage?

Media stories about HOLX stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hologic earned a daily sentiment score of 0.10 on Accern's scale. They also assigned news articles about the medical equipment provider an impact score of 44.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $38.36.

How big of a company is Hologic?

Hologic has a market capitalization of $10.63 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.03 on an earnings per share basis. Hologic employs 6,233 workers across the globe.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]

MarketBeat Community Rating for Hologic (HOLX)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		595 (Vote Outperform)
Underperform Votes:		402 (Vote Underperform)
Total Votes:		997

MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Hologic (NASDAQ:HOLX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

13 Wall Street analysts have issued ratings and price targets for Hologic in the last 12 months. Their average twelve-month price target is $47.5385, suggesting that the stock has a possible upside of 23.93%. The high price target for HOLX is $52.00 and the low price target for HOLX is $42.00. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.69	2.71	2.86	2.69
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 10 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$47.5385	$47.8571	$48.7857	$47.7692
Price Target Upside:	23.93% upside	28.44% upside	11.26% upside	29.49% upside

Hologic (NASDAQ:HOLX) Consensus Price Target History

Price Target History for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2018	Goldman Sachs	Set Price Target	Buy	$43.00	Low
2/9/2018	Canaccord Genuity	Reiterated Rating	Buy	$48.00	Low
2/9/2018	Royal Bank of Canada	Reiterated Rating	Hold	$44.00	High
2/9/2018	Needham & Company LLC	Reiterated Rating	Buy	$50.00	High
2/9/2018	Stifel Nicolaus	Downgrade	Buy -> Hold	$45.00 -> $42.00	High
1/19/2018	Deutsche Bank	Downgrade	Buy -> Hold	$49.00	Medium
1/4/2018	Bank of America	Upgrade	Neutral -> Buy	$50.00	Low
1/3/2018	Evercore ISI	Initiated Coverage	Outperform -> Outperform	$50.00	Medium
12/20/2017	Cowen	Upgrade	Buy	$52.00	Low
11/9/2017	Piper Jaffray	Reiterated Rating	Buy	$48.00	N/A
10/10/2017	Jefferies Group	Reiterated Rating	Buy	$49.00 -> $44.00	N/A
8/9/2017	Barclays	Reiterated Rating	Equal Weight	$53.00 -> $51.00	Low
5/14/2017	BTIG Research	Reiterated Rating	Buy	$47.00	Low
3/30/2017	Leerink Swann	Reiterated Rating	Outperform	$52.00	Low
7/28/2016	Morgan Stanley	Boost Price Target	Equal Weight	$38.00 -> $40.00	N/A
7/17/2016	UBS	Reiterated Rating	Buy	$45.00	N/A

(Data available from 4/25/2016 forward)

Hologic (NASDAQ:HOLX) Earnings History and Estimates Chart

Earnings by Quarter for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX) Earnings Estimates

2018 EPS Consensus Estimate: $2.14
2019 EPS Consensus Estimate: $2.50

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$0.49	$0.52	$0.50
Q2 2018	3	$0.51	$0.52	$0.52
Q3 2018	3	$0.54	$0.57	$0.56
Q4 2018	3	$0.53	$0.60	$0.56
Q1 2019	1	$0.60	$0.60	$0.60
Q2 2019	1	$0.60	$0.60	$0.60
Q3 2019	1	$0.65	$0.65	$0.65
Q4 2019	1	$0.65	$0.65	$0.65

Hologic (NASDAQ HOLX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018		$0.53					N/A
2/8/2018	Q1 2018	$0.50	$0.55	$785.80 million	$791.10 million	View	Listen
11/8/2017	Q4 2017	$0.49	$0.50	$792.54 million	$802.90 million	View	N/A
8/2/2017	Q3 2017	$0.49	$0.50	$799.70 million	$806.10 million	View	Listen
5/10/2017	Q2 17	$0.46	$0.50	$685.24 million	$715.40 million	View	N/A
2/1/2017	Q117	$0.51	$0.52	$725.01 million	$734.40 million	View	Listen
11/2/2016	Q416	$0.50	$0.52	$721.52 million	$726.80 million	View	N/A
7/27/2016	Q316	$0.48	$0.51	$703.66 million	$717.40 million	View	Listen
4/27/2016	Q216	$0.46	$0.47	$686.82 million	$693.30 million	View	Listen
1/27/2016	Q116	$0.42	$0.46	$688.68 million	$695.20 million	View	Listen
11/4/2015	Q415	$0.42	$0.43	$691.94 million	$702.80 million	View	Listen
7/29/2015	Q315	$0.39	$0.43	$653.85 million	$693.90 million	View	Listen
4/29/2015	Q215	$0.39	$0.41	$646.49 million	$655.50 million	View	N/A
1/28/2015	Q115	$0.36	$0.39	$630.79 million	$652.80 million	View	Listen
11/5/2014	Q414	$0.37	$0.43	$636.20 million	$660.60 million	View	Listen
7/30/2014	Q314	$0.34	$0.37	$621.89 million	$632.60 million	View	Listen
4/30/2014	Q214	$0.33	$0.37	$609.35 million	$625.00 million	View	Listen
2/3/2014	Q114	$0.31	$0.34	$609.65 million	$612.40 million	View	Listen
11/11/2013	Q413	$0.37	$0.39	$624.40 million	$622.10 million	View	Listen
8/5/2013	Q3 2013	$0.37	$0.38	$627.05 million	$626.10 million	View	Listen
5/6/2013	Q2 2013	$0.34	$0.35	$639.53 million	$619.10 million	View	Listen
2/4/2013	Q1 2013	$0.37	$0.38	$646.52 million	$644.60 million	View	Listen
11/12/2012	Q412	$0.36	$0.37	$581.12 million	$600.20 million	View	N/A
7/30/2012		$0.34	$0.35			View	N/A
4/30/2012		$0.33	$0.33			View	N/A
1/30/2012		$0.32	$0.34			View	N/A
11/7/2011		$0.33	$0.34			View	N/A
8/1/2011		$0.32	$0.32			View	N/A
5/2/2011		$0.28	$0.30			View	N/A
1/31/2011		$0.28	$0.30			View	N/A
11/8/2010	Q4 2010	$0.30	$0.30			View	N/A
8/2/2010	Q3 2010	$0.29	$0.30			View	N/A
5/3/2010	Q2 2010	$0.29	$0.29			View	N/A
2/1/2010	Q1 2010	$0.26	$0.29			View	N/A
11/9/2009	Q4 2009	$0.26	$0.28			View	N/A
8/3/2009	Q3 2009	$0.26	$0.29			View	N/A
5/4/2009	Q2 2009	$0.27	$0.29			View	N/A
2/2/2009	Q1 2009	$0.30	$0.31			View	N/A
11/11/2008	Q4 2008	$0.30	$0.30			View	N/A
7/30/2008	Q3 2008	$0.29	$0.33			View	N/A
5/1/2008	Q2 2008	$0.28	$0.29			View	N/A
1/31/2008	Q1 2008	$0.23	$0.25			View	N/A

(Earnings results data provided by Zacks Investment Research)

Hologic (NASDAQ:HOLX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Hologic (NASDAQ HOLX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.88%
Institutional Ownership Percentage: 97.42%

Insider Trading History for Hologic (NASDAQ:HOLX)

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ HOLX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/16/2018	Allison P. Bebo	SVP	Sell	7,000	$38.75	$271,250.00
3/15/2018	Charles J Dockendorff	Director	Buy	13,000	$38.80	$504,400.00
2/13/2018	Namal Nawana	Director	Buy	6,600	$37.88	$250,008.00	6,954
11/20/2017	Karleen Marie Oberton	VP	Sell	1,023	$39.84	$40,756.32
11/13/2017	Elaine Ullian	Director	Sell	9,282	$40.50	$375,921.00
11/8/2017	Karleen Marie Oberton	VP	Sell	1,256	$39.29	$49,348.24	9,406
11/6/2017	Karleen Marie Oberton	VP	Sell	538	$39.40	$21,197.20	8,343
10/10/2017	Lawrence M Levy	Director	Sell	9,596	$36.81	$353,228.76
10/9/2017	Lawrence M Levy	Director	Sell	7,138	$37.38	$266,818.44
9/7/2017	Lawrence M. Levy	Director	Sell	7,139	$39.04	$278,706.56
8/3/2017	Elaine Ullian	Director	Sell	6,902	$40.12	$276,908.24	23,810
7/17/2017	Karleen Marie Oberton	VP	Sell	4,704	$45.19	$212,573.76
7/3/2017	Elaine Ullian	Director	Sell	8,849	$45.28	$400,682.72	23,810
6/7/2017	Lawrence M Levy	Director	Sell	2,960	$44.54	$131,838.40	45,634
6/2/2017	Elaine Ullian	Director	Sell	8,938	$43.99	$393,182.62	23,810
5/30/2017	Peter J Valenti III	Insider	Sell	10,005	$43.44	$434,617.20	20,994
5/24/2017	Lawrence M Levy	Director	Sell	9,193	$42.93	$394,655.49	46,206
5/17/2017	Lawrence M Levy	Director	Sell	9,076	$42.80	$388,452.80	43,165
5/10/2017	Lawrence M Levy	Director	Sell	9,837	$45.34	$446,009.58	40,577
5/3/2017	Lawrence M Levy	Director	Sell	10,203	$45.00	$459,135.00	38,832
4/26/2017	Lawrence M Levy	Director	Sell	10,374	$44.46	$461,228.04	37,377
4/24/2017	Sally Crawford	Director	Sell	16,969	$44.00	$746,636.00	157,305
4/19/2017	Lawrence M Levy	Director	Sell	10,836	$42.49	$460,421.64	25,839
4/12/2017	Lawrence M Levy	Director	Sell	10,757	$42.45	$456,634.65	24,596
4/3/2017	Elaine Ullian	Director	Sell	9,104	$42.40	$386,009.60	23,810
3/8/2017	Sally Crawford	Director	Sell	17,396	$42.00	$730,632.00	152,305
2/3/2017	Elaine Ullian	Director	Sell	9,423	$39.54	$372,585.42	36,798
11/21/2016	Karleen Marie Oberton	VP	Sell	3,023	$38.32	$115,841.36	13,260
11/15/2016	Karleen Marie Oberton	VP	Sell	1,211	$36.55	$44,262.05	10,859
11/8/2016	Karleen Marie Oberton	VP	Sell	984	$38.57	$37,952.88	9,065
11/7/2016	Karleen Marie Oberton	VP	Sell	522	$38.53	$20,112.66	9,839
10/10/2016	Elaine Ullian	Director	Sell	18,236	$39.88	$727,251.68	42,898
10/10/2016	Karleen Marie Oberton	VP	Sell	31,470	$40.00	$1,258,800.00	17,005
7/21/2016	Nancy Leaming	Director	Sell	8,179	$37.00	$302,623.00	67,140
7/11/2016	Nancy Leaming	Director	Sell	6,221	$36.04	$224,204.84	55,053
6/1/2016	Lawrence M Levy	Director	Sell	17,794	$34.41	$612,291.54	23,257
5/27/2016	Peter J Valenti III	Insider	Sell	10,022	$33.83	$339,044.26	9,023
5/26/2016	Elaine Ullian	Director	Sell	6,896	$33.85	$233,429.60	31,157
5/26/2016	Karleen Marie Oberton	VP	Sell	4,228	$33.85	$143,117.80	8,819
2/24/2016	David R Lavance Jr	Director	Sell	11,621	$34.50	$400,924.50	20,983
11/10/2015	Lawrence M. Levy	Director	Sell	20,000	$40.70	$814,000.00	3,914
9/21/2015	Lawrence M. Levy	Director	Sell	5,000	$42.02	$210,100.00	3,914
9/8/2015	Wayne Wilson	Director	Sell	100,000	$39.00	$3,900,000.00	39,215
8/28/2015	Wayne Wilson	Director	Sell	11,146	$39.70	$442,496.20	39,215
8/26/2015	Wayne Wilson	Director	Sell	25,080	$38.61	$968,338.80	39,215
8/14/2015	Wayne Wilson	Director	Sell	13,257	$42.20	$559,445.40
6/3/2015	Lawrence M Levy	Director	Sell	10,000	$36.45	$364,500.00
5/22/2015	Lawrence M Levy	Director	Sell	5,000	$35.05	$175,250.00
5/4/2015	Lawrence M Levy	Director	Sell	10,000	$34.36	$343,600.00
3/6/2015	David R Lavance Jr	Director	Sell	12,000	$32.12	$385,440.00
2/13/2015	David R Lavance Jr	Director	Sell	8,000	$30.32	$242,560.00
1/29/2015	Karleen Marie Oberton	VP	Sell	18,997	$30.00	$569,910.00
11/11/2014	Karleen Marie Oberton	VP	Sell	2,609	$26.30	$68,616.70
11/3/2014	Karleen Marie Oberton	VP	Sell	12,507	$26.83	$335,562.81
10/31/2014	Roger D Mills	SVP	Sell	14,506	$26.00	$377,156.00
9/9/2014	Elaine Ullian	Director	Buy	7,900	$25.36	$200,344.00
5/9/2014	Rohan Hastie	SVP	Sell	6,037	$24.36	$147,061.32	1,500
5/8/2014	Glenn Muir	CFO	Sell	50,000	$24.26	$1,213,000.00	815,306
5/6/2014	Glenn Muir	CFO	Sell	196,000	$23.29	$4,564,840.00	815,306
5/6/2014	Lawrence Levy	Director	Sell	5,052	$23.58	$119,126.16
5/6/2014	Robert Lavallee	CAO	Sell	22,796	$23.58	$537,529.68	11,341
3/14/2014	David Lavance, Jr.	Director	Sell	5,500	$21.49	$118,195.00	122
3/14/2014	Glenn Muir	CFO	Sell	160,000	$21.51	$3,441,600.00	815,306
3/7/2014	Mark Casey	CAO	Sell	3,251	$22.53	$73,245.03	14,470
2/11/2014	Stephen Macmillan	CEO	Buy	38,600	$21.58	$832,988.00	237,500
2/7/2014	Stephen Macmillan	CEO	Buy	198,900	$20.78	$4,133,142.00	198,900
12/13/2013	Robert Lavallee	CAO	Sell	15,677	$21.70	$340,190.90	11,341
10/30/2013	Glenn P Muir	CFO	Sell	140,000	$22.32	$3,124,800.00
10/15/2013	Glenn P Muir	CFO	Sell	28,000	$22.12	$619,360.00
9/16/2013	Glenn Muir	CFO	Sell	28,000	$20.45	$572,600.00	825,891
9/13/2013	Robert Lavallee	CAO	Sell	2,500	$20.33	$50,825.00	19,090
8/20/2013	David Brady	SVP	Sell	42,328	$22.80	$965,078.40	27,749
8/15/2013	Glenn Muir	CFO	Sell	28,000	$22.49	$629,720.00	825,891
8/8/2013	Lawrence Levy	Director	Sell	5,000	$22.50	$112,500.00	5,052
8/8/2013	Mark Casey	CAO	Sell	14,804	$22.57	$334,126.28	20,632
7/19/2013	Robert H Lavallee	CAO	Sell	11,254	$20.89	$235,096.06
7/15/2013	Glenn P Muir	CFO	Sell	28,000	$19.78	$553,840.00
7/1/2013	Robert Cascella	CEO	Sell	20,000	$19.55	$391,000.00
6/17/2013	Glenn P Muir	CFO	Sell	28,000	$21.42	$599,760.00
6/3/2013	Robert Cascella	CEO	Sell	20,000	$20.71	$414,200.00
2/25/2013	Lawrence M Levy	Director	Sell	5,000	$22.00	$110,000.00
9/5/2012	Glenn P Muir	CFO	Sell	68,750	$19.96	$1,372,250.00
8/8/2012	Glenn P Muir	CFO	Sell	68,750	$19.69	$1,353,687.50

(Data available from 1/1/2013 forward)

Hologic (NASDAQ HOLX) News Headlines

Source:

Date	Headline
	BRIEF-FDA Approval Of Thinprep Integrated Imager Expands Automated Imaging For Pap Testing To More Labs www.reuters.com - April 25 at 8:48 AM
	Hologic (HOLX) Announces FDA Approval of ThinPrep www.streetinsider.com - April 25 at 8:48 AM
	FDA Approval of ThinPrep® Integrated Imager Expands Automated Imaging for Pap Testing to More Labs www.prnewswire.com - April 25 at 8:28 AM
	Women's Health Company Hologic and Actor, Director Aisha Tyler Partner to Help the One in Five Women Suffering in Silence with Heavy Periods finance.yahoo.com - April 24 at 5:12 PM
	Women's Health Company Hologic and Actor, Director Aisha Tyler Partner to Help the One in Five Women Suffering in ... www.prnewswire.com - April 24 at 8:47 AM
	Can Hologic (HOLX) Diagnostics Growth Recur in Q2 Earnings? finance.yahoo.com - April 23 at 4:53 PM
	Contrasting Check Cap (CHEK) & Hologic (HOLX) www.americanbankingnews.com - April 20 at 9:22 PM
	Why Erin Andrews Wants Women To Start Talking About The "C-Word" www.forbes.com - April 20 at 8:57 AM
	Hologic (HOLX) Expected to Announce Quarterly Sales of $780.06 Million www.americanbankingnews.com - April 20 at 2:34 AM
	Women Treated with Hologic's NovaSure® Endometrial Ablation System in New Study Reported Higher Amenorrhea ... www.prnewswire.com - April 19 at 5:11 PM
	Women Treated with Hologic's NovaSure® Endometrial Ablation System in New Study Reported Higher Amenorrhea Rates than Those Treated with Minerva finance.yahoo.com - April 19 at 5:11 PM
	Traders Buy Large Volume of Call Options on Hologic (HOLX) www.americanbankingnews.com - April 19 at 8:32 AM
	Check Cap (CHEK) & Hologic (HOLX) Critical Review www.americanbankingnews.com - April 18 at 11:08 PM
	4 MedTech Stocks to Keep in Good Books This Earnings Season finance.yahoo.com - April 18 at 5:17 PM
	Reviewing Check Cap (CHEK) & Hologic (HOLX) www.americanbankingnews.com - April 18 at 3:26 PM
	$0.53 Earnings Per Share Expected for Hologic (HOLX) This Quarter www.americanbankingnews.com - April 18 at 3:08 PM
	Hologic (HOLX) Upgraded to Sell at BidaskClub www.americanbankingnews.com - April 18 at 10:05 AM
	Goldman Remains Positive on Hologic (HOLX) www.streetinsider.com - April 18 at 8:50 AM
	Hologic (HOLX) PT Set at $43.00 by Goldman Sachs www.americanbankingnews.com - April 18 at 8:37 AM
	BidaskClub Lowers Hologic (HOLX) to Buy www.americanbankingnews.com - April 16 at 9:49 AM
	Check Cap (CHEK) vs. Hologic (HOLX) Critical Analysis www.americanbankingnews.com - April 15 at 3:25 AM
	Hologic (HOLX) Downgraded by BidaskClub www.americanbankingnews.com - April 14 at 12:49 AM
	Hologic (HOLX) Price Target Cut to $45.00 www.americanbankingnews.com - April 13 at 7:51 PM
	Hologic (HOLX) Price Target Cut to $49.00 www.americanbankingnews.com - April 13 at 3:16 PM
	Hologic's (HOLX) Sector Perform Rating Reaffirmed at Royal Bank of Canada www.americanbankingnews.com - April 12 at 3:58 PM
	Hologic (HOLX) Earns "Equal Weight" Rating from Barclays www.americanbankingnews.com - April 12 at 3:27 PM
	Edited Transcript of HOLX presentation 6-Mar-17 9:35pm GMT finance.yahoo.com - April 12 at 9:29 AM
	Hologic (HOLX) Rating Lowered to Sell at BidaskClub www.americanbankingnews.com - April 11 at 9:30 PM
	Reviewing Hologic (HOLX) & Check Cap (CHEK) www.americanbankingnews.com - April 10 at 1:41 AM
	Hologic Looks Iffy For Now seekingalpha.com - April 8 at 5:24 PM
	Financial Comparison: Check Cap (CHEK) vs. Hologic (HOLX) www.americanbankingnews.com - April 7 at 11:15 PM
	Analyzing Hologic (HOLX) & Check Cap (CHEK) www.americanbankingnews.com - April 7 at 12:18 AM
	Wall Street Largely Bullish on Hologic Stock in March finance.yahoo.com - April 4 at 3:47 PM
	Can HOLX Stock Rebound from Its Recent Lows? finance.yahoo.com - April 4 at 3:47 PM
	Hologic’s Viera Expected to Be Key Growth Driver for 2018 finance.yahoo.com - April 4 at 8:52 AM
	Hologic and Dexalytics Partner to Develop Software for Athletes finance.yahoo.com - April 4 at 8:52 AM
	Hologic to Announce Financial Results for the Second Quarter of Fiscal 2018 on Wednesday, May 2, 2018 www.prnewswire.com - April 3 at 5:03 PM
	Hologic (HOLX) Expected to Post Quarterly Sales of $780.06 Million www.americanbankingnews.com - April 3 at 3:21 AM
	Brokerages Anticipate Hologic (HOLX) to Announce $0.53 EPS www.americanbankingnews.com - April 1 at 3:17 PM
	Hologic (HOLX) Receives Average Recommendation of "Buy" from Brokerages www.americanbankingnews.com - April 1 at 8:16 AM
	Hologic (HOLX) vs. Essilor International (ESLOY) Critical Contrast www.americanbankingnews.com - March 31 at 9:10 AM
	Evercore ISI Initiates Coverage on Hologic (HOLX) www.americanbankingnews.com - March 30 at 11:43 PM
	Hologic (HOLX) Upgraded by Bank of America to "Buy" www.americanbankingnews.com - March 30 at 5:08 PM
	Hologic's Clarity HD & Intelligent 2D Systems Gain FDA Nod finance.yahoo.com - March 29 at 9:02 AM
	Hologic Forecasted to Earn FY2020 Earnings of $2.89 Per Share (HOLX) www.americanbankingnews.com - March 29 at 8:46 AM
	Hologic's Clarity HD & Intelligent 2D Systems Gain FDA Nod www.zacks.com - March 28 at 4:56 PM
	Piper Jaffray Remains Bullish on Hologic (HOLX) www.streetinsider.com - March 28 at 9:03 AM
	Hologic (HOLX) Reports FDA Approval of New Innovations on its 3Dimensions Mammography System www.streetinsider.com - March 27 at 9:07 AM
	FDA Approves New Innovations on Hologic's 3Dimensions™ Mammography System, the Fastest, Highest Resolution Breast Tomosynthesis System Ever(1) www.prnewswire.com - March 27 at 8:12 AM
	Hologic (HOLX) Lowered to Buy at Goldman Sachs www.americanbankingnews.com - March 26 at 9:15 AM

Hologic (NASDAQ:HOLX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Hologic (NASDAQ:HOLX) Income Statement, Balance Sheet and Cash Flow Statement

Hologic (NASDAQ HOLX) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff